Inhibition of transcription of the human c-myc protooncogene by intermolecular triplex

Area of Science:

• Molecular Biology
• Gene Regulation
• Oligonucleotide Therapeutics

Background:

• Triplex-forming oligonucleotides (TFOs) bind polypurine/polypyrimidine sequences in gene promoters, inhibiting transcription.
• The c-myc protooncogene is frequently overexpressed in human cancers, driving cell proliferation.
• Targeting c-myc offers a potential strategy for cancer therapy.

Purpose of the Study:

• To evaluate the in vivo efficacy of TFOs in inhibiting c-myc protooncogene expression.
• To assess the stability and binding affinity of modified phosphorothioate TFOs.
• To establish a cellular system for studying TFO-mediated gene inhibition.

Main Methods:

• Development of a cellular system using a c-myc promoter-luciferase reporter plasmid.
• Transfection of HeLa cells with phosphorothioate-modified TFOs targeting the c-myc protooncogene.
• Measurement of luciferase expression to quantify transcriptional inhibition.

Main Results:

• Phosphorothioate-modified TFOs demonstrated comparable binding affinity to phosphodiester oligonucleotides.
• TFOs targeting c-myc significantly reduced luciferase expression, indicating transcriptional inhibition.
• The study successfully demonstrated TFO-mediated inhibition of c-myc promoter activity in HeLa cells.

Conclusions:

• Modified TFOs can effectively inhibit c-myc protooncogene transcription in a cellular context.
• Triplex formation represents a promising gene-specific strategy for targeting protooncogene expression.
• This approach holds potential for developing novel anti-cancer therapeutics.